Decreased mRNA expression of CCL5 wRANTESx in Alzheimer's disease blood samples

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 1, 2012, Pages 61-65

  Kester, Maartje I ^a   Van Der Flier, Wiesje M ^a,b   Visser, Allerdien ^b   Blankenstein, Marinus A ^b   Scheltens, Philip ^a   Oudejans, Cees B ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Blood; Inflammation; MRNA

Indexed keywords

BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR B; RANTES; SOMATOMEDIN BINDING PROTEIN 6; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

AGED; ALZHEIMER DISEASE; CHEMOKINE CCL5; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84857843311     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.731     Document Type: Article

References (20)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13. (Pubitemid 37162569)
3. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009;46:235-40.
4. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engel-borghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55:820-5.
5. Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:539-40.
6. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359-62. (Pubitemid 350073592)
7. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
8. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009;30: 1895-901.
9. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phos-phorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-53.
10. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechteriakov S, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011;32:539-40.
11. Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann NY Acad Sci 2009;1180:56-67.
12. Johnstone M, Gearing AJ, Miller KM. A central role for astro-cytes in the inflammatory response to beta-amyloid; chemo-kines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999;93:182-93. (Pubitemid 29051564)
13. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuro-protective role. Neurobiol Aging 2010;31:8-16.
14. Teixeira AL, Reis HJ, Coelho FM, Carneiro DS, Teixeira MM, Vieira LB, et al. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. Biol Psychiatry 2008;64:891-5.
15. Ignatov A, Robert J, Gregory-Evans C, Schaller HC. RANTES stimulates Ca2q mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein-coupled receptor 75. Br J Pharmacol 2006;149:490-7. (Pubitemid 44658509)
16. Gerli R, Monti D, Bistoni O, Mazzone AM, Peri G, Cossarizza A, et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Dev 2000;121:37-46. (Pubitemid 32115398)
17. Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuro-pathol 1996;29:237-52. (Pubitemid 27016932)
18. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Kott E, et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 1994;52:147-52. (Pubitemid 24223248)
19. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994;16:29-35. (Pubitemid 24067673)
20. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998;12:215-27. (Pubitemid 29154993)